Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of palbociclib in recurrent or refractory advanced thymic epithelial tumor
KCT0003820Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in thymic malignancies (TET), sponsored by Pfizer. Started Aug 2017; status: recruiting.
02
Drugs
palbociclib
03
Conditions
thymic malignancies (TET)
Beyond the preview
Go deeper on KCT0003820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003820.